What Merck Holders Had To Weigh And You Can Reuse

If you only glanced at Merck’s recent headlines about acquisition charges and a swing from profit to loss, you might assume shareholders had a rough year. Investors who held Merck over the past year are up 66.5%, including dividends. That gap between messy accounting results and a powerful gain is hard to ignore. If you were weighing Merck on 2 October 2025, how could you have judged whether that kind of payoff was worth the risks on record then?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

This theme extends beyond Merck. See which of 35 healthcare AI stocks may still merit a closer look.

The Two Merck Narratives Investors Had To Weigh

Merck shares cost US$89.51 at the start of the period, and investors had to decide which Merck story felt more realistic.

The bullish narrative saw Fair Value at US$102, or 14% above the start price. It relied on revenue growth of 4.2%, a profit margin assumption of 33.7%, and a future P/E of 12.3x. Over 20 planned product launches and a much larger late-stage pipeline were expected to do the heavy lifting.

The more cautious view put Fair Value at US$74, or 17% below the start price. That narrative treated revenue growth of 2.8%, a 27.3% margin, and a future P/E of 12.1x as more realistic, while flagging risks around acquisitions and the impact of Keytruda’s eventual patent expiry.

What The Evidence Changed For The Merck Narratives

The clearest event for Merck was the Q2 2026 report. Revenue moved from US$15,806m in Q2 2025 to US$16,607m in Q2 2026, which helped the growth assumption in the bullish case. Profit told a different story. Net income excluding extra items turned from US$4,427m to a loss of US$1,335m and net margin shifted from 28.0% to a negative 8.0%. That profitability gap meant the evidence cut both ways.

The lesson is simple. When a thesis leans on higher margins, investors should look beyond sales or the product pipeline. It can be useful to track net income and the reported net margin each period to see whether the profit side of the story is actually reflected in the numbers.

What Merck's Run Already Prices In

Merck now trades at US$144 after a 66.5% gain over the past year, and the selected Narrative sees Fair Value below that level. The gap reflects concern that the recent surge prices in a smoother path through patent expiries and late stage development risk than the evidence guarantees.

A buyer here is effectively assuming KEYTRUDA pressure is largely contained and the next wave of oncology, cardiometabolic and flu products fills the earnings gap. The open question is how the specific safety, regulatory and uptake risks in this Narrative line up against that confidence.

"Management’s plan to grow through the KEYTRUDA loss of exclusivity by relying on more than US$70b in non risk adjusted mid 2030s revenue from over 20 new human health products depends on many launches and label expansions still ahead, and any combination of regulatory delays, competitive pressure or safety issues similar to those seen in I DXd and remigromig could leave total human health revenue and earnings meaningfully short of those ambitions."

The price and this Narrative do not agree. → Uncover what this Narrative says Merck is actually worth

One Step Beyond Merck

Merck’s story revolves around cancer drugs, heart treatments and vaccines. Your watchlist does not have to stop there.

Patients who benefit from Merck’s medicines often need ongoing help with weight and blood sugar. Another large drug maker is concentrating on that need.

This firm is developing obesity and diabetes treatments that reshape cardiometabolic care. It is also advancing research in brain disorders and cancer therapies.

Those efforts depend on access, reimbursement and pricing pressure staying manageable. If they succeed, its role alongside Merck could look very different.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 16% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com